Programs comparing candidates, dose, time or combinations to establish a basis for prioritization.
R&D service
Organoid efficacy screening
Compare single agents and combinations in tumor PDOs and other selected human organoid models to identify dose responses and differences across models.
View imageBreast cancer PDOs · plate-based ADC study
ADC dose response across two breast cancer PDO models
Two breast cancer PDO models show distinct ADC responses through morphology and viability curves. The plate-based approach also supports small-molecule and combination studies.
Study focus
Questions we can help answer
- 01How does response change across dose?
- 02What does the combination add over either single agent?
- 03How does response vary across models or samples?
STUDY APPROACH
Match the model and assays to your program
Conventional PDOs suit many tumor-epithelial efficacy comparisons; assess PDO 2.0 or a relevant co-culture when tissue, immune or spatial context is central.
Combine viability, morphology, apoptosis, imaging and mechanism-linked endpoints around the candidate modality and expected differences.
Define vehicle and positive controls, replication, assay window and prespecified comparison or hit criteria.
Prioritize candidates, dose windows and combinations, then define the next orthogonal or mechanism study.
Study workflow
Compare and rank candidates in consistent organoid studies
Compare candidates with dose-response, combination and mechanism-focused assays, supported by model QC and consistent experimental conditions.
Screen objective and candidate tiers
Define primary screening, confirmation, dose ranking or combination comparison, then stage the work by modality, candidate count and available evidence.
Model batch and assay window
Confirm identity, viability, well-to-well consistency, vehicle tolerance and positive-control response before expanding the screen.
Dose, combinations and multimodal readouts
Use single-agent dose series, combination matrices or longitudinal observation, interpreting viability alongside morphology, apoptosis, imaging or molecular readouts.
Confirmation and candidate ranking
Confirm preliminary hits with independent repeats or complementary endpoints, then rank candidates using potency, maximum effect, selectivity and data quality.
Study images and readouts
ADC response across two breast cancer PDO models
This plate-based ADC study uses morphology and dose-response curves to compare two breast cancer PDO models, informing dose range, replication and follow-on model selection.
View imageADC dose response: two breast cancer PDO models show distinct viability profiles across candidate ADC concentrations.
TRiCBIO breast cancer PDO ADC study dataView antibody distribution and ADC responseExpected study outputs
What you receive
Comparable response curves
Single agents, dose series or combination matrices use consistent experimental and analytical criteria.
Mechanism-linked readouts
An integrated analysis of viability, morphology, imaging, molecular or secreted readouts selected around the mechanism of action.
A traceable study report
Experimental conditions, model QC, raw data, analysis methods and key findings in a single study report.
Relevant model systems
Relevant model systems
Plate format and study scale are adapted to the model, candidate count and endpoints, with sample count, replicates, assay window and evaluation criteria defined before the study begins.
FAQ
Planning your study
Explore model selection, study planning and deliverables before your first discussion with our scientists.
How many PDO models are needed for a drug screen?
Model count depends on the study objective, tumor type, number of candidates and the heterogeneity you need to capture. After the initial discussion, we recommend a model panel and replication plan for an exploratory screen or expanded cohort.
Can the study compare doses, combinations and multiple candidates?
Yes. The study can include dose ranges, single-agent and combination arms, time points and controls, with viability, morphology or mechanism-related readouts used for comparison.
What is delivered from a PDO screening study?
Deliverables can include model and assay QC, raw data, dose-response and candidate comparisons, representative images, analysis and a study report. The exact deliverables are defined in the study plan.
PROJECT DISCUSSION
Plan an organoid efficacy study
Bring the candidate set, dose or combination plan, intended models and key endpoints. We’ll define the plate format, controls, replicates and comparison strategy with you.